LITFULO (Pfizer Australia Pty Ltd)
Product name
LITFULO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
104 (120 working days)
Active ingredients
ritlecitinib tosylate
Registration type
NCE/ NBE
Indication
LITFULO is indicated for the treatment of severe alopecia areata (AA) in adults and adolescents 12 years of age and older (see Section 5.1 Pharmacodynamic properties).